COX-2 inhibition by use of rofecoxib or high dose aspirin enhances ADP-induced platelet aggregation in fresh blood

Open Cardiovascular Medicine Journal

Volumn 4, Issue , 2010, Pages 198-205

  Borgdorff, Piet ^a   Handoko, M Louis ^a   Wong, Yeun Ying ^a   Tangelder, Geert Jan ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Aspirin; COX 2 inhibition; Platelets; Prostacyclin; Rofecoxib; Thromboxane

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; ARACHIDONIC ACID; CYCLOOXYGENASE 2 INHIBITOR; PLACEBO; ROFECOXIB; THROMBOXANE;

ADULT; ARTICLE; BLOOD FLOW; BLOOD SAMPLING; CANNULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SELECTIVITY; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; LOW DRUG DOSE; MALE; NORMAL HUMAN; PHOTOMETRY; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; TIME; TIME DEPENDENCY; VEIN PUNCTURE;

EID: 78249278174     PISSN: None     EISSN: 18741924     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Haara M, Heliovaara M, Arokoski JP, et al. Regular use of traditional analgesics predicts major coronary events: a cohort study. Ther Clin Risk Manage 2009; 5: 9-15.
2. Hudson M, Richard H, Pilote L. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. Br Med J 2005; 330: 1370.
3. McGettigan P, Henry D. Cardiovascular Risk and Inhibition of Cyclooxygenase: A Systematic Review of the Observational Studies of Selective and Nonselective Inhibitors of Cyclooxygenase 2. JAMA 2006; 296: 1633-44.
4. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Br Med J 2006; 332: 1302-8.
5. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional nonsteroidal anti-inflammatory drugs: population based nested casecontrol analysis. Br Med J 2005; 330: 1366.
6. Salinas G, Rangasetty UC, Uretsky BF, Birnbaum Y. The cycloxygenase 2 (COX-2) story: it's time to explain, not inflame. J Cardiovasc Pharmacol Ther 2007; 12:98-111.
7. Borgdorff P, Tangelder GJ, Paulus WJ. Cyclooxygenase-2 inhibitors enhance shear stress-induced platelet aggregation. J Am Coll Cardiol 2006; 48: 817-23.
8. Knijff-Dutmer EA, Kalsbeek-Batenburg EM, Koerts J, van de Laar MA. Platelet function is inhibited by non-selective non-steroidal anti-inflammatory drugs but not by cyclo-oxygenase-2-selective inhibitors in patients with rheumatoid arthritis. Rheumatology (Oxford) 2002; 41: 458-61.
9. Greenberg HE, Gottesdiener K, Huntington M, et al. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. J Clin Pharmacol 2000; 40: 1509-15.
10. Rinder HM, Tracey JB, Souhrada M, Wang C, Gagnier RP, Wood CC. Effects of meloxicam on platelet function in healthy adults: a randomized, double-blind, placebo-controlled trial. J Clin Pharmacol 2002; 42: 881-6.
11. Van Hecken A, Schwartz JI, Depre M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000; 40: 1109-20.
12. Leese PT, Recker DP, Kent JD. The COX-2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: results of a randomized controlled trial. J Clin Pharmacol 2003; 43: 504-13.
13. Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 2000; 40: 124-32.
14. Jermany J, Branson J, Schmouder R, Guillaume M, Rordorf C. Lumiracoxib does not affect the ex vivo antiplatelet aggregation activity of low-dose aspirin in healthy subjects. J Clin Pharmacol 2005; 45: 1172-78.
15. Graff J, Skarke C, Klinkhardt U, et al. Effects of selective COX-2 inhibition on prostanoids and platelet physiology in young healthy volunteers. J Thromb Haemost 2007; 5: 2376-85.
16. Qi R, Yatomi Y, Ozaki Y. Effects of incubation time, temperature, and anticoagulants on platelet aggregation in whole blood. Thromb Res 2001; 101:139-44.
17. Pirich C, Efthimiou Y, O'Grady J, Sinzinger H. Hyperalphalipoproteinemia and prostaglandin I2 stability. Thromb Res 1997; 88: 41-9.
18. Lucas FV, Skrinska VA, Chisolm GM, Hesse BL. Stability of prostacyclin in human and rabbit whole blood and plasma. Thromb Res 1986; 43: 379-87.
19. Polterauer P, Sinzinger H, Peskar BA. Biological half-life of prostacyclin and 6-oxo-PGF1 alpha levels in plasma of patients with colonic cancer. Prostaglandins Leukot Med 1986; 22: 249-58.
20. Borgdorff P, Fekkes D, Tangelder GJ. Hypotension caused by extracorporeal circulation: serotonin from pump-activated platelets triggers nitric oxide release. Circulation 2002; 106: 2588-93.
21. Jovicic A, Mandic S. Circadian variations of platelet aggregability and fibrinolytic activity in healthy subjects. Thromb Res 1991; 62: 65-74.
22. Depre M, Ehrich E, Van Hecken A, et al. Pharmacokinetics, COX2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. Eur J Clin Pharmacol 2000; 56: 167-74.
23. Ahuja N, Singh A, Singh B. Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects. J Pharm Pharmacol 2003; 55: 859-94.
24. Vesterqvist O. Rapid recovery of in vivo prostacyclin formation after inhibition by aspirin. Evidence from measurements of the major urinary metabolite of prostacyclin by GC-MS. Eur J Clin Pharmacol 1986; 30: 69-73.
25. Saniabadi AR, Belch JJ, Lowe GD, Barbenel JC, Forbes CD. Comparison of inhibitory actions of prostacyclin and a new prostacyclin analogue on the aggregation of human platelet in whole blood. Haemostasis 1987; 17: 147-53.
26. Buerkle MA, Lehrer S, Sohn HY, Conzen P, Pohl U, Krotz F. Selective inhibition of cyclooxygenase-2 enhances platelet adhesion in hamster arterioles in vivo. Circulation 2004; 110: 2053-2059.
27. Buchanan MR, Hirsh J. Effect of aspirin and salicylate on platelet-vessel wall interactions in rabbits. Arteriosclerosis 1984; 4: 403-6.
28. Forster W, Hoffmann W. Superior prevention of reinfarction by 30 mg/d aspirin compared with 1000 mg/d: results of a two years follow-up study in Cottbus. Biomed Biochim Acta 1988; 47: S248-S51.
29. Taylor DW, Barnett HJ, Haynes RB, et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet 1999; 353: 2179-84.
30. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003; 108: 1682-7.
31. Kong DF, Hasselblad V, Kandzari DE, Newby LK, Califf RM. Seeking the optimal aspirin dose in acute coronary syndromes. Am J Cardiol 2002; 90: 622-5.
32. Antithrombotic Trialist's Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
33. Harding SA, Din JN, Sarma J, et al. Flow cytometric analysis of circulating platelet-monocyte aggregates in whole blood: Methodological considerations. Thromb Haemost 2007; 98: 451-6.
34. Inoue T, Hayashi M, Uchida T, Takayanagi K, Hayashi T, Morooka S. Significance of platelet aggregability immediately after blood sampling and effect of cigarette smoking. Platelets 2001; 12: 415-8.
35. Roy S. Effects of smoking on prostacyclin formation and platelet aggregation in users of oral contraceptives. Am J Obstet Gynecol 1999; 180: S364-S8.
36. Cha JK, Jeon HW, Kang MJ. ADP-induced platelet aggregation in acute ischemic stroke patients on aspirin therapy. Eur J Neurol 2008; 15: 1304-8.
37. Barstad RM, Orvim U, Hamers MJ, Tjonnfjord GE, Brosstad FR, Sakariassen KS. Reduced effect of aspirin on thrombus formation at high shear and disturbed laminar blood flow. Thromb Haemost 1996; 75: 827-32.
38. Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005; 142: 481-9.
39. Moncada S, Vane JR. Interrelationships between prostacyclin and thromboxane A2. Ciba Found Symp 1980; 78: 165-83.
40. FitzGerald GA, Brash AR, Falardeau P, Oates JA. Estimated rate of prostacyclin secretion into the circulation of normal man. J Clin Invest 1981; 68: 1272-6.
41. Karniguian A, Legrand YJ, Caen JP. Prostaglandins: specific inhibition of platelet adhesion to collagen and relationship with cAMP level. Prostaglandins 1982; 23: 437-57.
42. den Dekker E, Gorter G, Heemskerk JW, Akkerman JW. Development of platelet inhibition by cAMP during megakaryocytopoiesis. J Biol Chem 2002; 277: 29321-9.
43. Fisch A, Tobusch K, Veit K, Meyer J, Darius H. Prostacyclin receptor desensitization is a reversible phenomenon in human platelets. Circulation 1997; 96: 756-60.
44. Murata T, Ushikubi F, Matsuoka T, et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997; 388: 678-82.
45. Arehart E, Stitham J, Asselbergs FW, et al. Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition. Circ Res 2008; 102: 986-93.
46. Bolego C, Buccellati C, Radaelli T, et al. eNOS, COX-2, and prostacyclin production are impaired in endothelial cells from diabetics. Biochem Biophys Res Commun 2006; 339: 188-90.
47. Barnard K. Viewpoint: an explanation for the cardiovascular effects of bevacizumab and rofecoxib? Circulation 2006; 114: f173-f5.
48. Aoyama T, Yui Y, Morishita H, Kawai C. Prostaglandin I2 half-life regulated by high density lipoprotein is decreased in acute myocardial infarction and unstable angina pectoris. Circulation 1990; 81: 1784-91.